Common Contracts
5 similar Underwriting Agreement contracts by Progenics Pharmaceuticals Inc
2,600,000 Shares Progenics Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 24th, 2007 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
Progenics Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 2,600,000 shares (the “Firm Shares”) of the Company’s common stock, $0.0013 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 390,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
Progenics Pharmaceuticals, Inc. 2,500,000 Shares Common Stock ($0.0013 par value) Underwriting AgreementUnderwriting Agreement • September 15th, 2005 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
Progenics Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) 2,500,000 shares (the “Firm Shares”) of Common Stock, $0.0013 par value (“Common Stock”), of the Company. The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. To the extent there are no additional Underwriters listed on Schedule I other than you, the term Underwriters shall mean either the singular or plural as the context requires. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 375,000 shares (the “Additional Shares”) of Common Stock from the Company for the purpose of covering over allotments in connection with the sale of the Firm Shares. The Firm Shares and the Additional Shares are collectively called the “Securities.”
Progenics Pharmaceuticals, Inc. 1,532,467 Shares Common Stock ($0.0013 par value) Underwriting AgreementUnderwriting Agreement • June 13th, 2005 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
Progenics Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) 1,532,467 shares of Common Stock, $0.0013 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus or the Prospectus, as the case may be; and
Progenics Pharmaceuticals, Inc. 2,000,000 Shares Common Stock ($0.0013 par value) Underwriting AgreementUnderwriting Agreement • April 5th, 2005 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
Progenics Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) 2,000,000 shares of Common Stock, $0.0013 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus or the Prospectus, as the case may be; and
Progenics Pharmaceuticals, Inc. 2,750,000 Shares* Common Stock ($0.0013 par value) Underwriting AgreementUnderwriting Agreement • November 6th, 2003 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
Citigroup Global Markets Inc. CIBC World Markets Corp. Lazard Frères & Co. LLC Legg Mason Wood Walker, Incorporated Punk, Ziegel & Company, L.P. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013
